Homi-Lung has successfully passed its first Horizon Europe project review, with external experts and the European Commission Project Officer confirming that the project’s implementation is satisfactory and recommending only targeted improvements for the next phase.
In their consolidated assessment of Reporting Period 1 (January 2024–June 2025), reviewers highlight excellent scientific, technical and organisational progress, with work “fully aligned” with the Description of Action and the project timeline. They note that Homi-Lung has launched its core clinical studies (CAP, HAP and Healthy Lung), completed ethics and regulatory approvals, and started recruitment across multiple European sites, supported by high-standard procedures for sampling, data capture and monitoring.
Beyond the clinical rollout, the review points to strong project management and governance, with deliverables and milestones submitted on time, and early outputs already emerging across multi-omics, computational modelling and preclinical work.
The experts also provide clear next steps: increase the visibility of results as datasets mature (e.g., preprints, policy summaries or interactive visualisations), broaden outreach formats (including podcasts or short videos), begin early internal IP screening, and ensure alignment with regulatory and standardisation pathways for biomarkers and clinical decision-support tools.
Overall, the message is simple: Homi-Lung is progressing strongly, delivering on its commitments, and entering the next project period with a clear set of priorities to maximise impact. We warmly thank all partners and contributors, inside and outside the consortium, for their continued commitment and dedication.